New analyses find increased efficacy of Erbitux in 1st-line metastatic colorectal cancer New analyses of two randomized, controlled clinical trials investigating Erbitux (cetuximab) in the treatment of 1st-line metastatic colorectal cancer (mCRC) highlight the increased efficacy of Erbitux in patients with 'normal,'...
A Southern mystery In 2004, strange things were happening when people living in the Southern United States received Erbitux, an anticancer drug.After Erbitux was approved, the first three patients that oncologist Bert O'Neil treated at the...
Colorectal cancer patients to get test Ontario's Health Ministry says it will start requiring colorectal cancer patients to take a new test that can determine whether the drug it purchases for them in the United States actually works.However, it did not provide details...
Colorectal cancer patients in Ontario to get test Ontario's Health Ministry says it will start requiring colorectal cancer patients to take a new test that can determine whether the drug it purchases for them in the United States actually works.However, it did not provide details on...
Erbitux - Enhanced Efficacy Demonstrated in Patients With KRAS Wild-Type Tumors in 1st-Line Metastatic Colorec New analyses of two randomized, controlled clinical trials investigating Erbitux (cetuximab) in the treatment of 1st-line metastatic colorectal cancer (mCRC) highlight the increased efficacy of Erbitux in patients with normal,...
Premium Company Profile - ImClone Systems - New Research Report on Companies and Markets Company-Profile/Premium-Comp ..Introduction After undergoing a turbulent past, ImClone Systems is on its road to recovery following the commercial launch of Erbitux for head and neck cancer in March 2006.
Since then, the strong...
DxS Launches Cancer Mutation Kit for K-RAS in Australia New diagnostic assists clinicians in selecting appropriate cancer therapy for patients Manchester, UK, 1 July 2008 - DxS, a personalised medicine company and leaders in the provision of companion diagnostics, has today announced the launch...
Big Pharma pulls out of U.K. trials There's more bad news today for the U.K.'s drug development industry.Pfizer, Roche and Merck Serono have all decided to cut back on clinical research there, according to the Financial Times.
The problem, companies say, is that too few U...
Landscape for Lung Cancer Therapies is Focus of New Post-ASCO MedPredict Report SCOTTSDALE, Ariz.The big news at the recent (ASCO) meeting was the presentation of the Erbitux FLEX clinical trial data showing increased overall survival in EGFR-positive first-line non-small cell lung cancer.
In light of these...
Landscape for Lung Cancer Therapies is Focus of New Post-ASCO MedPredict Report SCOTTSDALE, Ariz., June 26 /PRNewswire/ -- MedPredict has published a new report in its oncology series entitled 'Thought Leader Insight & Analysis: Lung Cancer,' designed to provide critical strategic insight for pharma and biotech...
Landscape for Lung Cancer Therapies is Focus of New Post-ASCO MedPredict Report SCOTTSDALE, Ariz., June 26 /PRNewswire/ -- MedPredict has published a new report in its oncology series entitled 'Thought Leader Insight & Analysis: Lung Cancer,' designed to provide critical strategic insight for pharma and biotech...
Landscape for Lung Cancer Therapies is Focus of New Post-ASCO MedPredict Report SCOTTSDALE, Ariz., June 26 /PRNewswire/ -- MedPredict has published a new report in its oncology series entitled 'Thought Leader Insight & Analysis: Lung Cancer,' designed to provide critical strategic insight for pharma and biotech...
UK'S healthcare watchdog recommends use of Merck KGaA's Erbitux in head cancer healthcare watchdog recommends use of KGaA's Erbitux in head cancer Ticker Meta Trade Frequency Old Level 2 Changes Order book Toplist Monitor Streaming News Phrases Money Words Advanced FilterX Sector Sheet ScatterX Money Words UK...
Landscape for Lung Cancer Therapies is Focus of New Post-ASCO MedPredict Report SCOTTSDALE, Ariz., June 26 /PRNewswire/ -- MedPredict has published a new report in its oncology series entitled 'Thought Leader Insight & Analysis: Lung Cancer,' designed to provide critical strategic insight for pharma and biotech...
Landscape for Lung Cancer Therapies is Focus of New Post-ASCO MedPredict Report SCOTTSDALE, Ariz., June 26 /PRNewswire/ -- MedPredict has published a new report in its oncology series entitled 'Thought Leader Insight & Analysis: Lung Cancer,' designed to provide critical strategic insight for pharma and biotech...
Landscape for Lung Cancer Therapies is Focus of New Post-ASCO MedPredict Report SCOTTSDALE, Ariz., June 26 /PRNewswire/ -- MedPredict has published a new report in its oncology series entitled 'Thought Leader Insight & Analysis: Lung Cancer,' designed to provide critical strategic insight for pharma and biotech...
Landscape for Lung Cancer Therapies is Focus of New Post-ASCO MedPredict Report /PRNewswire/ -- MedPredict has published a new report in its oncology series entitled 'Thought Leader Insight & Analysis: Lung Cancer,' designed to provide critical strategic insight for pharma and biotech companies with a stake in the...
Landscape for Lung Cancer Therapies is Focus of New Post-ASCO MedPredict Report SCOTTSDALE, Ariz., June 26 /PRNewswire/ -- MedPredict has published a new report in its oncology series entitled 'Thought Leader Insight & Analysis: Lung Cancer,' designed to provide critical strategic insight for pharma and biotech...
Landscape for Lung Cancer Therapies is Focus of New Post-ASCO MedPredict Report SCOTTSDALE, Ariz., June 26 /PRNewswire/ -- MedPredict has published a new report in its oncology series entitled 'Thought Leader Insight & Analysis: Lung Cancer,' designed to provide critical strategic insight for pharma and biotech...
Landscape for Lung Cancer Therapies is Focus of New Post-ASCO MedPredict Report SCOTTSDALE, Ariz., June 26 /PRNewswire/ -- MedPredict has published a new report in its oncology series entitled 'Thought Leader Insight & Analysis: Lung Cancer,' designed to provide critical strategic insight for pharma and biotech...
Landscape for Lung Cancer Therapies is Focus of New Post-ASCO MedPredict Report SCOTTSDALE, Ariz., June 26 /PRNewswire/ -- MedPredict has published a new report in its oncology series entitled 'Thought Leader Insight & Analysis: Lung Cancer,' designed to provide critical strategic insight for pharma and biotech...
Landscape for Lung Cancer Therapies is Focus of New Post-ASCO MedPredict Report SCOTTSDALE, Ariz., June 26 /PRNewswire/ -- MedPredict has published a new report in its oncology series entitled 'Thought Leader Insight & Analysis: Lung Cancer,' designed to provide critical strategic insight for pharma and biotech...
Landscape for Lung Cancer Therapies is Focus of New Post-ASCO MedPredict Report The big news at the recent American Society of Clinical Oncology (ASCO) meeting was the presentation of the Erbitux FLEX clinical trial data showing increased overall survival in EGFR-positive first-line non-small cell lung cancer.
Landscape for Lung Cancer Therapies is Focus of New Post-ASCO MedPredict Report MedPredict has published a new report in its oncology series entitled 'Thought Leader Insight & Analysis: Lung Cancer,' designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for...
Landscape for Lung Cancer Therapies is Focus of New Post-ASCO MedPredict Report SCOTTSDALE, Ariz., June 26 /PRNewswire/ -- MedPredict has published a new report in its oncology series entitled 'Thought Leader Insight & Analysis: Lung Cancer,' designed to provide critical strategic insight for pharma and biotech...
